US Pharma MarketingGSK to launch Phase 3 test of mRNA flu vaccine with newer formulation
GSK to start a Phase 3 trial of its mRNA seasonal flu vaccine after Phase 2 data topped traditional shots on immune response. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The…
GSK on Tuesday said it will start a late-stage trial of its mRNA vaccine for seasonal influenza after the candidate delivered “higher immune responses” than traditional vaccines in a Phase 2 test.
The UK pharma ...
Source: Endpoints News